|Day Low/High||24.40 / 25.09|
|52 Wk Low/High||21.62 / 40.24|
Doug Kass shares his thoughts on how 2017 will be the year of 'the Dude.'
Insiders at these companies -- including Medtronic and Medicines -- have been scooping up shares of their own stock lately.
Oragenics (NYSE MKT:OGEN.BC), a leader in the development of new antibiotics against infectious disease and developing effective treatments for oral mucositis, today announced it presented at the American Society for...
- Granted Patent Provides Composition of Matter Protection for SYN-005 to at Least 2035 -
There's a striking lack of volatility, and that's a flashing red warning signal.
Doug Kass shares his thoughts on managing and selecting short-term trades.
The most recent short interest data was recently released for the 11/15/2016 settlement date, and Intrexon Corp is one of the most shorted stocks of the Russell 3000, based on 12.58 "days to cover" versus the median component at 4.41. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
Doug Kass shares his thoughts on a strange, possibly ominous day, and a 'ludicrous forecast.'
Genetically engineered mosquito that fights Aedes aegypti achieves high approval rate among residents of city where it is applied
Doug Kass shares his thoughts on closed-end municipal bond funds.
In highlights from this week's trading diary and posts, Kass tells us about Friday's positives and retail's woes.
Capacity to Produce 60 Million Friendly™ Aedes per Week can Help Protect Up to 3 Million Brazilians from Primary Vector for Zika, Dengue and other Viruses
Former Commanding General of U.S. Army Corps of Engineers to Drive Worldwide Deployment of Oxitec's Friendly™ Mosquito
Startups to Utilize ActoBiotics™ Platform to Develop Innovative Treatments for Celiac Disease and Chronic Rhinosinusitis
Demand is quite healthy and markets are not going into the abyss, Cramer says.